Genitope IPO Would Fund Phase III Cancer Vaccine Trials
Genitope plans to use proceeds from an initial public offering to fund enrollment of 360 patients in a pivotal study of the MyVax therapeutic cancer vaccine
Genitope plans to use proceeds from an initial public offering to fund enrollment of 360 patients in a pivotal study of the MyVax therapeutic cancer vaccine